BLASUBCUTANEOUSINJECTABLE7 Generics Approved
Approved
Jun 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
NOVOLOG (insulin aspart) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NovoLog (insulin aspart) is a rapid-acting insulin analog approved in 2000 for subcutaneous injection in diabetes management. It mimics the body's natural insulin response to meals and is used to control blood sugar in patients with type 1 and type 2 diabetes. The drug works by facilitating glucose uptake into muscle and fat cells while suppressing hepatic glucose production.
$517MPart D
LOE ApproachingDeclining
Product faces patent expiration with moderate competitive intensity (30/100); commercial teams are likely shifting toward lifecycle defense and transition planning rather than expansion.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
Started Jul 2024
54 enrolled
Healthy Participants
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Started Jul 2023
414 enrolled
Diabetes
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Started Nov 2021
679 enrolled
Diabetes Mellitus, Type 2
A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
Started Apr 2021
200 enrolled
Diabetes Mellitus, Type 2
Worked on NOVOLOG at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.